摘要
随着我国进入老龄化社会,骨质疏松症已经成为严重威胁老年人健康的常见疾病之一。骨质疏松表现为骨量减少、易发生骨折。影像学检查包括X线平片、CT、MRI、核医学检查和骨密度测量,在骨质疏松症的防治中发挥重要作用。由于骨质疏松症防治涉及多学科和多专业合作,但目前缺乏统一的共识,影响着学科发展和规范临床服务。为此,由来自放射、骨科、内分泌、影像技术和核医学专业专家组成的共识专家组,在充分复习国际指南、共识、文献以及国内最新研究成果的基础上,结合我国医疗实际情况,针对骨质疏松的影像学和骨密度测量技术、诊断标准和鉴别诊断形成共识,为临床医务工作者在骨质疏松的影像学与骨密度临床应用方面提供科学、具体的指导,促进我国骨质疏松症的影像学与骨密度诊断规范化发展。
With the aging of the society,osteoporosis becomes one of the common diseases threatening the health of elderly population in China,and there is increasing concern on this matter.Osteoporosis is characterized with bone loss and susceptible to fragility fractures,where various imaging modalities like X-ray,CT,MRI and nuclear medicine along with bone mineral density assessment play a very important role in the diagnosis and management of osteoporosis.The treatment of osteoporosis requires multidisciplinary team work,the lack of consensus in the imaging and bone mineral density examination(BMD)of osteoporosis hampered the quality of service and patient care.Therefore,a panel consisting of experts from radiology,orthopedic,endocrinology,medical imaging and nuclear medicine reviewed the international guidelines,consensus and literature,and the newly data from China and considering the clinical practice in China,the panel reached this consensus to help guide the diagnosis of osteoporosis with imaging and BMD.This consensus will provide guideline and standard on the imaging and BMD assessment of osteoporosis and the criteria for diagnosis.
作者
无
程晓光
袁慧书
程敬亮
翁习生
徐浩
高剑波
徐文坚
吴艳
刘华
黄晨
无;Cheng Xiaoguang;Yuan Huishu;Cheng Jingliang;Weng Xisheng;Xu Hao;Gao Jianbo(Bone and Joint Group of Chinese Society of Radiology,Chinese Medical Association;Musculoskeletal Radiology Society of Chinese Medical Doctors Association;Osteoporosis Group of Chinese Orthopedic Association,Chinese Medical Association;Bone Density Goup of Chinese Society of Imaging Technology,Chinese Medical Association;不详)
出处
《中国骨质疏松杂志》
CAS
CSCD
北大核心
2020年第9期1249-1256,共8页
Chinese Journal of Osteoporosis
基金
国家重点研发计划(2020YFC2004900)
北京市自然科学基金-海淀原始创新联合基金(L172019)。